Health Conditions A-Z Cancer Breast Cancer What Is the Survival Rate of Stage 4 (Metastatic) Breast Cancer? By Jessie Van Amburg Jessie Van Amburg Jessie Van Amburg is a freelance writer and editor who has covered health, nutrition, and lifestyle topics for top media outlets including Women's Health Magazine, TIME.com, and Well+Good. She lives in the Hudson Valley with her husband and cats. health's editorial guidelines Updated on October 28, 2024 Medically reviewed by Marla Anderson, MD Medically reviewed by Marla Anderson, MD Marla Anderson, MD, FACS, is a board-certified surgeon who specializes in the surgical treatment of breast disease. learn more Alvaro Medina Jurado / Getty Images Stage 4 (metastatic) breast cancer has been shown to have a five-year survival rate of 31%. People with earlier-stage breast cancer tend to have a higher five-year survival rate of 99%. Keep in mind that life expectancy depends on several factors, such as the type of cancer, where it's spread, and how well it responds to treatments. Metastatic breast cancer is an advanced stage of the disease in which cancer cells have spread beyond the breasts and lymph nodes. Cancer cells commonly affect the bones, liver, lungs, and brain. Updated Screening Guidelines In 2024, the U.S. Preventive Services Task Force (USPSTF) released new guidelines recommending that women get screened for breast cancer every other year between the ages of 40 and 74. Some women may need an annual screening, especially if you're at a higher risk of breast cancer or if you have dense breast tissue. What Is Metastatic Breast Cancer? Metastatic breast cancer, which is also known as stage 4 breast cancer, has spread beyond the breast and the surrounding lymph nodes to other body parts. About 20% to 30% of people with breast cancer will develop metastatic breast cancer after an initial earlier-stage diagnosis. Just 6% of people have metastatic breast cancer when they're first diagnosed. "Basically what's happening is the cancer cells are growing ... they get into the bloodstream which then allows them to travel to distant sites [in the body]," Evelyn Toyin Taiwo, MD, hematologist and oncologist at Weill Cornell Medicine and NewYork-Presbyterian Brooklyn Methodist Hospital, told Health. Metastatic breast cancer cells can spread anywhere in the body. They most often take up residence in the bones, liver, lungs, and brain. It's unclear how or why certain cancers metastasize and others don't or why breast cancer cells spread to these specific regions. The type of cancer may play a role in where it spreads. Triple-negative breast cancer, for example, often spreads to the lungs. Estrogen-receptor (ER) positive breast cancer commonly spreads to the bones. Metastatic Breast Cancer Survival Rates Metastatic breast cancer is the most advanced stage of breast cancer, and there's no cure for it. The five-year survival rate for people with metastatic breast cancer is 31%. People with this form of breast cancer are just 31% as likely to be alive five years from diagnosis as people who don't have cancer. This may sound grim, but there are a few important things to keep in mind about survival rates. There's a lot of variability since many factors affect survival rate, such as: Age at diagnosis How cancer responds to treatment Other existing health conditions Type of breast cancer (e.g., triple-negative or HER2-positive) Where cancer cells spread in the body (e.g., bones, lungs, liver, brain, or elsewhere), and how extensive it is The life expectancy for someone with metastatic breast cancer who's been on the same treatment for three years is likely going to be better than if the cancer doesn't respond to treatment. A person who has one bone lesion (cancer site) will similarly fare better than if cancer cells have spread to multiple sites. Understanding the Prognosis Official metastatic breast cancer survival rates can be misleading. "The average includes all the people who do worse than the average and all the people who do better," Nancy Lin, MD, an oncologist who specializes in breast cancer at Dana-Farber Cancer Institute in Boston, told Health. How the survival rate is calculated also matters. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) only factors in people with a specific type of metastatic breast cancer. Dr. Lin often relies on clinical trial data for better estimates since these trials tend to include other types of metastatic breast cancer. This isn't to say that SEER data is bad or inaccurate. SEER plays a critical role in providing experts with data to inform treatment, care, and more. Survival rates generally tend to be a tad outdated. The good news: "There's been significant progress in terms of survival [from metastatic breast cancer]," said Dr. Taiwo. A review published in 2018 found that the average life expectancy from metastatic breast cancer increased from 21 months (slightly less than two years) to 38 months (just over three years) between 1990 and 2010. This number has likely improved since then, thanks to improved treatment options. Treatment Options Metastatic breast cancer isn't curable. There are still many treatments available to control the disease, help extend a person's life, and improve their quality of life. Treatments that manage metastatic breast cancer include: Chemotherapy, particularly for metastatic triple-negative breast cancer Immunotherapy, which helps the immune system target and destroy cancer cells Medicines that strengthen the bones Radiation therapy to manage pain caused by bone lesions Targeted hormone therapy for metastatic hormone-receptor-positive breast cancer (e.g., ER-positive breast cancer) A Quick Review The metastatic breast cancer survival rate is lower than that of earlier stages of breast cancer. Remember that several factors can impact life expectancy. It's important to consider the type of cancer, where it's spread, and how well it responds to treatments. Treatments and care advancements have come a long way to improve the odds significantly. You may feel empowered that there are many treatments out there to manage symptoms and improve your quality of life. Frequently Asked Questions Can metastatic breast cancer go into remission? Remission means that imaging tests don't detect cancer cells, but the condition can return in the future. Treatments like chemotherapy, hormone therapy, and targeted therapy can help metastatic breast cancer go into remission.There's no cure for metastatic breast cancer. The goal of treatment is to manage symptoms, extend life expectancy, and improve quality of life. What is the first red flag of metastatic breast cancer? The signs and symptoms of metastatic breast cancer depend on where the cancer cells have spread. Some of the first red flags generally include:Loss of energyLumps in your breastPainTrouble breathingSwollen lymph nodesUnintentional weight loss Can you survive 10 years with stage 4 breast cancer? It's possible to survive 10 years with stage 4 breast cancer, although it's rare. Research has shown that 13% of people with metastatic HER2-positive breast cancer were in remission 10 years after diagnosis. Was this page helpful? Thanks for your feedback! Tell us why! Other Submit 13 Sources Health.com uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. American Cancer Society. Survival rates for breast cancer. American Cancer Society. What are advanced and metastatic breast cancers? American Cancer Society. Treatment of stage IV (metastatic) breast cancer. U.S. Preventive Services Task Force. Breast cancer: Screening. Xie Y, Gou Q, Zhang Y, et al. Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. BMC Cancer. 2022;22(1):385. doi:10.1186/s12885-022-09454-y Kim SJ, Patel I, Park C, et al. Palliative care and healthcare utilization among metastatic breast cancer patients in U.S. Hospitals. Sci Rep. 2023;13(1):4358. doi:10.1038/s41598-023-31404-2 Bado I, Gugala Z, Fuqua S, et al. Estrogen receptors in breast and bone: From virtue of remodeling to vileness of metastasis. Oncogene 36, 4527–4537 (2017). doi:10.1038/onc.2017.94 National Cancer Institute. What is SEER? Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: Meta-analysis and systematic review. JNCI Cancer Spectrum. 2018;2(4):pky062. doi:10.1093/jncics/pky062 Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25-36. doi:10.4137/BCBCR.S32783 Nicolini A, Barak V, Biava P, et al. The use of immunotherapy to treat metastatic breast cancer. Curr Med Chem. 26(6):941-962. doi:10.2174/0929867325666180209124052 Steenbruggen TG, Linn SC, Rodenhuis S, et al. Ongoing remission nineteen years after high-dose chemotherapy for oligometastatic breast cancer; what can we learn from this patient? Cureus. 2015;7(12):e433. doi:10.7759/cureus.433 Wong Y, Raghavendra AS, Hatzis C, et al. Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313-318. doi:10.1634/theoncologist.2018-0213